Friday, February 22, 2013

• Elan Provides Update Post Restructuring Announcement of Tysabri CollaborationBusiness Wire (Fri, Feb 22)

Thursday, February 21, 2013

• BioMarin Earnings: An Early Lookat Motley Fool (Thu, Feb 21)

Wednesday, February 20, 2013

• Can the Human Brain Project Crack the Code for Big Pharma?at Motley Fool (Wed, Feb 20)

Monday, February 18, 2013

• Has Avanir Pharmaceuticals Become the Perfect Stock?at Motley Fool (Mon, Feb 18)

Tuesday, February 12, 2013

• Why Elan Cut Its Ties To Tysabriat Motley Fool (Tue, Feb 12)
• Elan Announces Filing of Annual Report on Form 20-F for Year Ended December 31, 2012Business Wire (Tue, Feb 12)

Monday, February 11, 2013

• Data on Biogen Hemophilia CandidatesZacks (Mon, Feb 11)
• Has Elan Become the Perfect Stock?at Motley Fool (Mon, Feb 11)
• Stock Downgrades: Elan Losing Its Panacheat Minyanville (Mon, Feb 11)

Friday, February 8, 2013

• Post-Tysabri, Will Elan Waste The Windfall?at Seeking Alpha (Fri, Feb 8)
• Audiocast: Unusual strategy in ElanoptionMONSTER (Fri, Feb 8)

Thursday, February 7, 2013

• 2 Hot Stocks to Trade (or Not)at TheStreet (Thu, Feb 7)
• Elan Beats on Sales, Loses TysabriZacks (Thu, Feb 7)
• 4 Stocks Making Movesat Motley Fool (Thu, Feb 7)
• Today's Market News To Trade On: 5 Stocks Moving On Newsat Seeking Alpha (Thu, Feb 7)
• Elan downgraded to Sector Perform from Outperform at RBC Capitaltheflyonthewall.com (Thu, Feb 7)

Wednesday, February 6, 2013

• Why Elan Shares Plungedat Motley Fool (Wed, Feb 6)
• 1 Blockbuster Biotech Dealat Motley Fool (Wed, Feb 6)
• Biogen Idec Pays Elan $3.25 Billion For Tysabri: Do We Leave, Or Stay?at Seeking Alpha (Wed, Feb 6)
• A Win-Win Multiple Sclerosis Deal?at Motley Fool (Wed, Feb 6)
• Micron Announces Convertible Notes and 3 Heavily Traded Shares Demanding Attentionat Wall St. Cheat Sheet (Wed, Feb 6)
• Elan Corporation's CEO Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha (Wed, Feb 6)
• Stocks Lower In Choppy Trade; Aruba, Trimble Slideat Investor's Business Daily (Wed, Feb 6)
• Who's Going to Buy This Orphan Drugmaker?at Motley Fool (Wed, Feb 6)
• Biogen Idec Paying $3.25 Billion for Full Rights to Tysabriat Motley Fool (Wed, Feb 6)

Add ELN News to My Yahoo!